A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
A legfontosabb adatok
- Hol
- Abington, Atlanta, Austin, Boulder, Brandon, Canton, Cincinnati, Colorado Springs, Columbia, Cullman, Dallas, Denver, Dublin, Huntersville, Kansas City, Lansing, Lincoln, Little Rock, Los Angeles, Macon, Madison, Miami, Middletown, Peoria, Phoenix, San Antonio, San Francisco, Stanford, Sterling Heights, Stockbridge, Sugar Land, Winter Park és Wyomissing (Egyesült Államok)Mind a 33 helyszín megnézése
- Fázis
- 2/3. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Forrás: NCT06767683: ki vehet részt
Helyszínek itt: Egyesült Államok
- Abington, PennsylvaniaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Atlanta, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Austin, TexasHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Boulder, ColoradoHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Brandon, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Canton, OhioHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Cincinnati, OhioHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Colorado Springs, ColoradoHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Columbia, South CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Cullman, AlabamaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Dallas, TexasHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Denver, North CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Dublin, OhioHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Huntersville, North CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Kansas City, KansasHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Lansing, MichiganHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Lincoln, NebraskaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Little Rock, ArkansasHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Los Angeles, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Macon, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Madison, WisconsinHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Miami, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Middletown, New JerseyHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Peoria, IllinoisHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Phoenix, ArizonaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- San Antonio, TexasHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- San Francisco, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Stanford, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Sterling Heights, MichiganHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Stockbridge, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Sugar Land, TexasHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Winter Park, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
- Wyomissing, PennsylvaniaHospital not named in the registryContact: Director, Global Clinical ServicesRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Alkermes, Inc.
- Azonosító
- NCT06767683EU 2024-519822-18-00
- A regiszteradat frissítve
- 2026. október 9.
- Eredeti leírás
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.A teljes eredeti leírásKevesebb
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
Bevonási feltételek: Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1); Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the duration of study (for all subjects).
Kizáró feltételek: Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening; Developed a new clinically significant health condition, ECG or laboratory abnormality, in the opinion of the Investigator or Sponsor, may impact the subject's participation in the study; Is currently pregnant, breastfeeding, or planning to become pregnant during the study.